Advanced Radiation Therapy for Prostate Cancer in Ireland
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a newer type of radiation therapy called SABR (stereotactic ablative body radiotherapy) for men with prostate cancer. It aims to deliver high doses of radiation precisely to the tumor in fewer treatments, potentially reducing side effects and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a male 18 years or older
- You have been diagnosed with prostate adenocarcinoma (confirmed by biopsy within 18 months) with a Gleason score of 7 or lower
- Your cancer is localized (stages T1c–T3a) with no spread to lymph nodes or distant organs
- Your PSA level is 30 ng/ml or lower (or 15 ng/ml if taking 5-alpha reductase inhibitors)
- You have not received prior radiation to the pelvis or active prostate cancer treatment (except hormone therapy or watchful waiting)
- You are in good enough health for radiotherapy and have a life expectancy of at least 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
This study is testing whether giving a higher dose of radiation to the tumour, while still keeping the dose to nearby organs safe, can improve control of the cancer. It's for people with early-stage lung cancer (or a single spot of cancer in the lung from another cancer) who are not suitable for or refuse surgery. The treatment specifically targets tumours that are near the chest wall, where a standard approach might not be safe, and uses a special planning scan to guide the dose.
This trial tests a type of radiation that adjusts to changes in your prostate during treatment. It aims to improve accuracy and reduce side effects for men with intermediate- or high-risk prostate cancer.
This study tests whether a very focused type of radiation (SABR) can control a small number of prostate cancer spots that are starting to grow while you’re already on abiraterone. It may help by treating only the areas that are progressing, while other areas remain controlled.
This trial tests whether two “ablative” (high-dose, focused) radiation treatments can work well for men with favorable-risk prostate cancer. It looks at whether the treatments are practical and safe, especially for urinary side effects.
This trial studies a more sped-up radiation schedule for men with certain local prostate cancers, given together with hormone therapy. It aims to keep cancer control while possibly reducing treatment time and making care easier.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.